Published 11 days ago • loading... • Updated 11 days ago

Eurofins Viracor Launches Assays for Pneumococcal Antibody Detection, Expanding Serotype Coverage to Support Immunocompromised Patient Care

In Lenexa, Eurofins Viracor recently launched a multiplexed bead-based IgG assay covering 32 Streptococcus pneumoniae serotypes, including those in PCV21, and said it is the first lab to detect antibodies to every vaccine serotype.
To expand serotype coverage, the launch added nine additional serotypes including 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B, responding to clinician needs and aiding immunity monitoring for immunocompromised patients.
Validations aligned to WHO standards showed 100% accuracy at the 1 µg/mL IgG cutoff, with higher responses in immunocompetent individuals, Eurofins Viracor said.
Leveraging its diagnostic expertise, Eurofins Viracor said it supports broad assay deployment as a subsidiary of Eurofins Scientific, published on October 26, 2024.
Framed as an innovation by Eurofins Viracor, the assay was presented at IDWeek October 2025 and shared on the webpage published Oct. 26, 2024, supporting CDC-recommended vaccines.

Insights by Ground AI

13 Articles

abc12/WJRT

+12 Reposted by 12 other sources

Center

Eurofins Viracor Launches Assays for Pneumococcal Antibody Detection, Expanding Serotype Coverage to Support Immunocompromised Patient Care

LENEXA, Kan., Jan. 20, 2026 /PRNewswire/ -- Eurofins Viracor announces the launch of a multiplexed bead-based assay to detect IgG responses to currently available pneumococcal vaccines, including the recently approved Pneumococcal 21-valent Conjugate Vaccine (PCV21). These Pneumococcal Antibody assays—PCV15 (15…

11 days ago·Flint, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year